BIO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

706.57M

+5.85%

2.824

-2.61%

601.86M

+2.81%

2.536

-0.15%

669.91M

+2.81%

2.732

+4.66%

Estimates Revision

The market is revising Downward the revenue expectations for Bio-Rad Laboratories, Inc. (BIO) for FY2025, with the revenue forecasts being adjusted by -0.21% over the past three months. During the same period, the stock price has changed by 7.71%.

Revenue Estimates for FY2025

Revise Downward

-0.21%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.53%

In Past 3 Month

Stock Price

Go Up

+7.71%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast BIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIO is 369.25 USD with a low forecast of 325.00 USD and a high forecast of 437.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

325.00

Averages

369.25

High

437.00

Current: 0.000

Low

325.00

Averages

369.25

High

437.00

Citi

Buy

maintain

$350 -> $375

2025-10-30

Reason

Citi

Price Target

$350 -> $375

2025-10-30

maintain

Buy

Reason

Citi raised the firm's price target on Bio-Rad to $375 from $350 and keeps a Buy rating on the shares. The firm cites higher peer multiples for the target bump post the company's Q3 report.

Wells Fargo

Equal Weight

maintain

$265 -> $340

2025-10-30

Reason

Wells Fargo

Price Target

$265 -> $340

2025-10-30

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Bio-Rad to $340 from $265 and keeps an Equal Weight rating on the shares. The firm says shares of Bio-Rad should be flat on the in-line quarter and stable full year guide. Not surprisingly, Bio-Rad is cautious on 2026 growth prospects, but still expects to deliver margin expansion even on muted revenue growth, Wells adds.

Wells Fargo

Brandon Couillard

Equal Weight

maintain

$245 -> $265

2025-08-01

Reason

Wells Fargo

Brandon Couillard

Price Target

$245 -> $265

2025-08-01

maintain

Equal Weight

Reason

Wells Fargo analyst Brandon Couillard raised the firm's price target on Bio-Rad to $265 from $245 and keeps an Equal Weight rating on the shares. The firm believes shares of Bio-Rad should open higher on the solid Q2 beat and upward guidance revision. Commentary on U.S. academic demand was surprisingly constructive. Overall, a positive step toward "new-ish" management building more credibility with Street, says Wells.

UBS

NULL -> Buy

maintain

$310 -> $325

2025-08-01

Reason

UBS

Price Target

$310 -> $325

2025-08-01

maintain

NULL -> Buy

Reason

UBS raised the firm's price target on Bio-Rad to $325 from $310 and keeps a Buy rating on the shares.

Wells Fargo

Equal Weight

downgrade

$260 -> $245

2025-06-08

Reason

Wells Fargo

Price Target

$260 -> $245

2025-06-08

downgrade

Equal Weight

Reason

Wells Fargo lowered the firm's price target on Bio-Rad to $245 from $260 and keeps an Equal Weight rating on the shares. The firm reduced estimates to reflect revised assumptions for life science growth in the second half of 2025 and 2026.

Wells Fargo

Brandon Couillard

Hold

Maintains

$320 → $270

2025-04-17

Reason

Wells Fargo

Brandon Couillard

Price Target

$320 → $270

2025-04-17

Maintains

Hold

Reason

Valuation Metrics

The current forward P/E ratio for Bio Rad Laboratories Inc (BIO.N) is 29.16, compared to its 5-year average forward P/E of 35.88. For a more detailed relative valuation and DCF analysis to assess Bio Rad Laboratories Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

35.88

Current PE

29.16

Overvalued PE

47.23

Undervalued PE

24.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

22.17

Current EV/EBITDA

17.25

Overvalued EV/EBITDA

29.26

Undervalued EV/EBITDA

15.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.63

Current PS

3.14

Overvalued PS

6.30

Undervalued PS

2.95

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 333305.8% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BIO News & Events

Events Timeline

No data

News

4.0

2025-11-25TipRanks

3 Stocks Signaling 'Buy' Opportunities for Investors Based on Technical Analysis

9.5

2025-10-30Yahoo Finance

Bio-Rad Laboratories Reports Increase in Q3 Non-GAAP Earnings and Revenue

4.0

2025-10-23NASDAQ.COM

BIO Surpasses Average Analyst Expectations

People Also Watch

Frequently Asked Questions

What is Bio Rad Laboratories Inc (BIO) stock price today?

The current price of BIO is 323.82 USD — it has increased 1.49 % in the last trading day.

What is Bio Rad Laboratories Inc (BIO)'s business?

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

What is the price predicton of BIO Stock?

What is Bio Rad Laboratories Inc (BIO)'s revenue for the last quarter?

Bio Rad Laboratories Inc revenue for the last quarter amounts to 653.00M USD, increased 0.50 % YoY.

What is Bio Rad Laboratories Inc (BIO)'s earnings per share (EPS) for the last quarter?

Bio Rad Laboratories Inc. EPS for the last quarter amounts to -12.70 USD, decreased -154.41 % YoY.

What changes have occurred in the market's expectations for Bio Rad Laboratories Inc (BIO)'s fundamentals?

How many employees does Bio Rad Laboratories Inc (BIO). have?

Bio Rad Laboratories Inc (BIO) has 7700 emplpoyees as of January 09 2026.

What is Bio Rad Laboratories Inc (BIO) market cap?

Today BIO has the market capitalization of 8.61B USD.